These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 23144619

  • 21. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 22. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [Abstract] [Full Text] [Related]

  • 23. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy.
    Gasnault J, Kahraman M, de Goër de Herve MG, Durali D, Delfraissy JF, Taoufik Y.
    AIDS; 2003 Jul 04; 17(10):1443-9. PubMed ID: 12824781
    [Abstract] [Full Text] [Related]

  • 24. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL.
    Acta Neurol Scand; 2017 Nov 04; 136 Suppl 201():37-44. PubMed ID: 29068484
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 04; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho Mde J, Comini-Frota ER, Domingues RB, Ferreira ML, Finkelsztejn A, Gama PD, Gomes S, Gonçalves MV, Kaimen-Maciel DR, Morales Rde R, Muniz A, Ruocco HH, Salgado PR, Albuquerque LB, Gama RA, Georgeto S, Lopes J, Oliveira CL, Oliveira FT, Safanelli J, Saldanha PC, Satomi M.
    Arq Neuropsiquiatr; 2013 Oct 04; 71(10):780-2. PubMed ID: 24212514
    [Abstract] [Full Text] [Related]

  • 29. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F, Ladwig A, Opala S, Laurent S, Schroeter M, Goelz S, Fink GR, Wieland U, Silling S, Warnke C.
    Mult Scler Relat Disord; 2024 Jul 04; 87():105664. PubMed ID: 38735204
    [Abstract] [Full Text] [Related]

  • 30. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 31. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C, Ibba G, Bertoli D, Capra R, Uleri E, Serra C, Imberti L, Dolei A.
    J Neurovirol; 2020 Feb 30; 26(1):133-137. PubMed ID: 31468472
    [Abstract] [Full Text] [Related]

  • 32. Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.
    de Goër de Herve MG, Dekeyser M, Hendel-Chavez H, Maillart E, Labeyrie C, Adams D, Moreau T, Lubetzki C, Papeix C, Stankoff B, Gasnault J, Taoufik Y.
    Front Immunol; 2024 Feb 30; 15():1416074. PubMed ID: 39086476
    [Abstract] [Full Text] [Related]

  • 33. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA, Iannetta M, Pontecorvo S, Anzivino E, Prezioso C, Rodio DM, Morreale M, D'Abramo A, Oliva A, Lichtner M, Cortese A, Frontoni M, Pietropaolo V, Francia A, Mastroianni CM, Vullo V, Ciardi MR.
    Biomed Res Int; 2018 Feb 30; 2018():5297980. PubMed ID: 29682547
    [Abstract] [Full Text] [Related]

  • 34. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
    Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, Batson S, Koralnik IJ.
    Ann Neurol; 2014 Jun 30; 75(6):925-34. PubMed ID: 24687904
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C, Papadopoulos V, Raftopoulou S, Mavragani CP, Evangelopoulos ME.
    J Neurol Sci; 2024 Jun 15; 461():123046. PubMed ID: 38761670
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.